Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FKAP7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,106
Award facts
- Contract value 100% obligated
- $13,105.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $13,105.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml autoinjector. This delivery order, issued on December 5, 2025, with an ultimate completion date of December 29, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and serve as the prime contractor with no identified subcontractors.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036. The PPV-G GEN V program is DLA's comprehensive $30.3 billion pharmaceutical supply strategy designed to support Department of Defense military healthcare facilities worldwide. As an authorized PPV-G GEN V prime vendor contractor, DMS Pharmaceutical Group is positioned to provide a full spectrum of pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables to meet the recurring medical supply needs of the federal military medical system globally.
Quick answers
Who was awarded contract SPE2DR26FKAP7?
SPE2DR26FKAP7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FKAP7 worth?
The government has obligated $13,106 on SPE2DR26FKAP7.
Is contract SPE2DR26FKAP7 an order under another contract?
Yes. SPE2DR26FKAP7 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAP7 competed?
The extent of competition for SPE2DR26FKAP7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award